142 related articles for article (PubMed ID: 34543060)
1. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
Soulières D; Gelmon KA
J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060
[No Abstract] [Full Text] [Related]
2. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Ratain MJ; Tannock IF; Lichter AS
J Clin Oncol; 2021 Nov; 39(31):3423-3426. PubMed ID: 34543056
[No Abstract] [Full Text] [Related]
3. Sotorasib: First Approval.
Blair HA
Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
[TBL] [Abstract][Full Text] [Related]
4. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
5. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
6. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
Wright KM
Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
[TBL] [Abstract][Full Text] [Related]
7. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
8. Sotorasib effective in KRAS-mutant NSCLC.
Sidaway P
Nat Rev Clin Oncol; 2021 Aug; 18(8):470. PubMed ID: 34140669
[No Abstract] [Full Text] [Related]
9. Sotorasib (Lumakras) for NSCLC.
Med Lett Drugs Ther; 2023 Jun; 65(1678):e104-e105. PubMed ID: 37339098
[No Abstract] [Full Text] [Related]
10. Outpacing cancer.
Dorans K
Nat Med; 2009 Jul; 15(7):718-22. PubMed ID: 19584848
[No Abstract] [Full Text] [Related]
11. Brain Mural Cells Express CAR T-cell Target.
Cancer Discov; 2020 Dec; 10(12):1781-1782. PubMed ID: 33097477
[TBL] [Abstract][Full Text] [Related]
12. Advances in the battle against lung tumour resistance.
Furlow B
Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524
[No Abstract] [Full Text] [Related]
13. What's Next for Sotorasib in NSCLC?
Cancer Discov; 2023 May; 13(5):1033-1034. PubMed ID: 36929750
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
[TBL] [Abstract][Full Text] [Related]
15. Sotorasib.
Am J Health Syst Pharm; 2021 Sep; 78(18):1656-1657. PubMed ID: 34219153
[No Abstract] [Full Text] [Related]
16. After decades, progress against an 'undruggable' cancer target.
Kaiser J
Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875
[No Abstract] [Full Text] [Related]
17. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].
Giroux Leprieur E; Fallet V; Wislez M
Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961
[TBL] [Abstract][Full Text] [Related]
19. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
Saleh K; Khalife N; Felefly T
Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
[No Abstract] [Full Text] [Related]
20. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
